Does Glibenclamide Interact with Eltrombopag Olamine?
CDI records a moderate classification for Glibenclamide and Eltrombopag Olamine. The stored summary is: OATP1B1 substrate; monitor for excessive exposure and consider dose reduction if appropriate. The mechanism involves oatp1b1 transporter inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Glibenclamide Class
- Sulfonylurea
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
OATP1B1 transporter inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Glibenclamide and your doctor is considering prescribing Eltrombopag Olamine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider